Humacyte posts bigger-than-expected Q4 loss

Reuters03-27
Humacyte posts bigger-than-expected Q4 loss

Overview

  • US bioengineered tissue maker's Q4 net income and operating income missed analyst expectations

  • Company reported $0.5 mln Q4 revenue, driven by Symvess sales and research collaborations

  • Company received $1.475 mln purchase commitment for Symvess clinical evaluation in Saudi Arabia

Outlook

  • Company expects top-line interim results from V012 Phase 3 hemodialysis study by early June 2026

  • Humacyte plans to submit supplemental BLA for ATEV hemodialysis indication in second half of 2026

  • Company aims to begin first-in-human trial for coronary tissue engineered vessel in second half of 2026

Result Drivers

  • US LAUNCH - Co said Q4 sales were driven by commercial launch of Symvess in US and growing awareness among surgeons

  • INTERNATIONAL INTEREST - $1.475 mln purchase commitment for Symvess clinical evaluation and outreach in Saudi Arabia highlighted international demand

  • INVENTORY RESERVE - Co recorded $8.9 mln inventory reserve due to lack of consistent sales history, impacting cost of goods sold and net loss

Company press release: ID:nGNX5PsycG

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

Miss

-$24.80 mln

-$23.30 mln (5 Analysts)

Q4 Operating Income

Miss

-$30.84 mln

-$22.78 mln (5 Analysts)

Q4 Basic EPS

-$0.13

Q4 Operating Expenses

$31.30 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Humacyte Inc is $3.50, about 349.6% above its March 26 closing price of $0.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment